Organogenesis Reports Q1 2026 Earnings with Significant Revenue and Profit Declines
Organogenesis (ORGO) reported a significant decline in revenue for the first quarter of 2026, primarily due to challenges in its advanced wound care segment. Net product revenue dropped by 58% year-over-year to $36.3 million, with surgical and sports medicine revenue remaining stable at $6.8 million.
Tickers: $ORGO
Topics: inventory write-downs operating loss revenue decline